The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1757-Patient Cohort

    January 2021 in “ Cureus ”
    Flavio Cadegiani, Ricardo Ariel Zimerman, Bruno Campello de Souza … Andy Goren
    Studysummary This study suggests that the AndroCoV clinical scoring system may be a more sensitive and cost-effective tool for diagnosing COVID-19 compared to RT-PCR-SARS-CoV-2 tests, potentially reducing diagnostic delays and false negatives.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on assets.cureus.com →
    Discuss this study in the Community →

    Research cited in this study 12

    1. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1757-Patient Cohort Cureus · 2021
    2. Clinical Diagnosis of COVID-19: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool Based on a 1,757-Patient Cohort (The AndroCoV Clinical Scoring for COVID-19 Diagnosis) Research Square (Research Square) · 2021
    3. COVID-19, Androgens, and Androgenic Alopecia Dermatological reviews · 2020
    4. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin, or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients bioRxiv (Cold Spring Harbor Laboratory) · 2020
    5. Hydroxychloroquine, Nitazoxanide, and Ivermectin Have Similar Effects in Early COVID-19: A Head-to-Head Comparison of the Pre-AndroCoV Trial Research Square (Research Square) · 2020
    6. Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19 Journal of the European Academy of Dermatology and Venereology · 2020
    7. Azithromycin With Nitazoxanide, Hydroxychloroquine or Ivermectin, With or Without Dutasteride, for Early Stage COVID-19: An Open-Label Prospective Observational Study in Males With Mild-to-Moderate COVID-19 (The Pre-AndroCoV Male Trial) Research Square (Research Square) · 2020
    8. An Open-Label Prospective Observational Study of Antiandrogen and Non-Antiandrogen Early Pharmacological Approaches in Females with Mild-to-Moderate COVID-19: The Pre-AndroCoV Female Trial medRxiv (Cold Spring Harbor Laboratory) · 2020
    9. Repurposing Existing Drugs for COVID-19: An Endocrinology Perspective BMC Endocrine Disorders · 2020
    10. Androgen Receptor Genetic Variant Predicts COVID-19 Disease Severity: A Prospective Longitudinal Study of Hospitalized COVID-19 Male Patients Journal of the European Academy of Dermatology and Venereology · 2020
    11. Spironolactone: An Anti-Androgenic and Anti-Hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Frontiers in Medicine · 2020
    12. Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign Journal of The American Academy of Dermatology · 2020